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Abstract
Background: Adoptive cell transfer (ACT) is a promising cancer immunotherapeutic strategy that remains
ineffective for a large subset of patients. ACT with memory CD8+ T cells (Tmem) has been shown to have superior
efficacy compared to traditional ACT with effector CD8+ T cells (Teff). Teff and Tmem have complementary
physiological advantages for immunotherapy, but previous publications have not examined ACT using a
combination of Teff and Tmem.
Methods: Splenocytes harvested from Ly5.1+/C57BL/6 mice during and after infection with lymphocytic
choriomeningitis virus (LCMV) were used to generate bona fide effector and memory CD8+ T cells specific for the
LCMV epitope peptide GP33. Congenic Ly5.2+/C57BL/6 mice were inoculated with B16F10 melanoma cells
transfected to express very low levels of GP33, then treated with ACT 7 days later with GP33-specific Teff, Tmem, or a
combination of Teff + Tmem.
Results: Inhibition of melanoma growth was strongest in mice receiving combinatorial ACT. Although
combinatorial ACT and memory ACT resulted in maximal intratumoral infiltration of CD8+ T cells, combinatorial ACT
induced stronger infiltration of endogenous CD8+ T cells than Tmem ACT and a stronger systemic T cell
responsiveness to tumor antigen. In vitro assays revealed rapid but transient melanoma inhibition with Teff and
gradual but prolonged melanoma inhibition with Tmem; the addition of Tmem enhanced the ability of Teff to inhibit
melanoma in a manner that could be reproduced using conditioned media from activated Tmem and blocked by
the addition of anti-IL-2 blocking antibody.
Conclusions: These findings suggest that a novel combinatorial approach that takes advantage of the unique and
complementary strengths of tumor-specific Teff and Tmem may be a way to optimize the efficacy of adoptive
immunotherapy.
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Background
Adoptive cell transfer (ACT) is a promising strategy for
cancer immunotherapy that involves the isolation, ex-
pansion, and infusion of tumor-specific CD8+ T cells.
When combined with interleukin-2 (IL-2) and lympho-
depletion, ACT has led to complete and durable tumor
regression in up to 20% of patients with metastatic mel-
anoma [1]. Despite this, ACT remains ineffective for a
large subset of patients.
Traditionally, ACT involves the use of terminally
differentiated CD8+ effector T cells (Teff ) collected
from tumor-infiltrating lymphocytes (TILs). When
naïve T cells encounter antigen, they clonally expand
and differentiate into Teff that have the ability to rap-
idly clear cells expressing their cognate antigen [2, 3].
Following antigen clearance, the majority of Teff then
undergo apoptosis, while a small population of
antigen-specific CD8+ memory T cells (Tmem) persists
long-term and can rapidly proliferate upon antigen
re-exposure [2, 3].
The use of different T cell subsets is one potential way
to improve the efficacy of ACT. Less-differentiated ef-
fector cells have been shown to have superior antitumor
immunity compared to terminally-differentiated cells,
potentially due to a number of mechanisms such as de-
creased IL-2 production and increased apoptosis with
further differentiation [4, 5]. Our laboratory and others
have also demonstrated that ACT with Tmem is more ef-
fective than ACT with Teff or naïve T cells [6, 7]. Tmem
appear to be uniquely resistant to melanoma-induced
suppression and generate a stronger intratumoral im-
mune response [7, 8].
No previous publications have explored performing
ACT with a combination of Tmem and Teff. Although Teff
are prone to apoptosis, we hypothesized that this limita-
tion could be offset by the innate proliferative ability of
Tmem, with Teff contributing to initial tumor control and
Tmem to later tumor control. In a murine model, we
compared the efficacy of ACT using bona fide Teff,
Tmem, and a combination of both. We utilized a novel
melanoma tumor expressing very low levels of a viral
peptide in order to dissect the biological effects of
peptide-specific CD8+ T cells of true effector and mem-
ory differentiation. This methodology enables us to
examine the therapeutic implications of bona fide ef-
fector and memory tumor-specific CD8+ T cells in a
manner not possible with standard murine melanoma
targets like GP100. Using in vitro experiments, we ex-
plored the temporal cell killing patterns and paracrine
effects of these T cell subsets. We discovered that the
combination of Teff + Tmem led to the strongest control
of melanoma tumor growth, potentially due to comple-




Seven- to eight-week old female congenic C57BL/6
mice with allele Ly5.1+ (T cell donor mice) or allele
Ly5.2+ (T cell recipient mice) were purchased from
Taconic (Hudson, NY) and maintained in sterile hous-
ing. All mouse work was reviewed and approved by the
University of Wisconsin and William S. Middleton
Memorial VA Hospital and VA Ann Arbor Healthcare
Animal Care and Use Committees.
Tumor cell lines and effector/memory cell generation
Viral infections and tumor inoculations were performed
per our previously published protocols [7, 9, 10]. In
brief, Ly5.1+/C57BL/6 mice were infected with 2 × 105
PFU of Armstrong strain lymphocytic choriomeningitis
virus (LCMV; gift from Marulasiddappa Suresh,
University of Wisconsin) via intraperitoneal injection to
generate CD8+ T cells specific for GP33, a class
I MHC-restricted LCMV surface glycoprotein. Spleno-
cytes were harvested 8 days after infection (at which
time LCMV peptide-specific CD8+ T cells are of effector
differentiation) to obtain bona fide Teff (as evidenced by
CD127low/KLRG1high expression) and 50–80 days after
infection (at which time LCMV peptide-specific CD8+ T
cells are of memory differentiation) to obtain bona fide
Tmem (as evidenced by CD127
high/KLRG1low expression)
[7, 8]. The yield of GP33-specific memory CD8+ T cells
was increased by adoptively transferring Ly5.1+/C57BL/
6 mice with 103 Ly5.1+/CD8+ T cells derived from sple-
nocytes of Ly5.1+/P14 TCR transgenic mice (C57BL/6
background mice with CD8+ T cell specificity for GP33
[7]. The spontaneous mouse melanoma cell line B16F10
was transfected with a plasmid encoding GP33, and
poorly immunogenic clones with low levels of GP33 ex-
pression were selected to create a new B16GP33 cell line,
which we have previously demonstrated to be of compar-
ably low immunogenicity as parental B16F10 [9, 10]. This
line was cultured in RPMI-1640 medium (Mediatech,
Herndon, VA) with 10% fetal bovine serum, 2 mM L-gluta-
mine, 100 μg/mL streptomycin, and 100 U/mL penicillin
(Life Technologies, Inc., Grand Island, NY). Ly5.2
+/C57BL/6 mice received subcutaneous injections of 1 ×
106 B16GP33 cells suspended in serum-free RPMI-1640
to generate flank melanoma tumors.
Adoptive cell transfer
Adoptive cell transfer was performed per our previously
published protocol [7, 8, 10]. As previously observed,
GP33-specific CD8+ T cells typically comprised approxi-
mately 8–10% of splenocytes harvested from effector
and memory T cell donor mice [7, 8]. After obtaining
splenocytes from mice infected with LCMV, magnetic
bead separation columns (Miltenyi, Auburn, CA) were
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used to isolate CD8+ T cells. Flow cytometry was per-
formed to quantify the percentage of tumor-specific
GP33-specific CD8+ T cells. 105 GP33-specific CD8+
Teff, Tmem, or 5 × 10
4 Teff + 5 × 10
4 Tmem were adoptively
transferred via retro-orbital intravenous injections into
B16F10- or B16GP33 melanoma-bearing mice at specific
time points after tumor inoculation.
MTT assay
For multiple timepoints, a total number of 2 × 104
GP33-specific CD8+ Teff and Tmem or both were separ-
ately co-cultured with 2 × 104 B16GP33 melanoma cells
at an overall effector:target ratio of 1:1 in 48-well plates
in the presence of 10 ng/mL recombinant human IL-2
(BD Biosciences, San Jose, CA) for MTT assays as previ-
ously described [7]. T cells were characterized and iso-
lated using the methodology described for adoptive cell
transfer. Viable B16GP33 melanoma cells were quanti-
fied using the Celltiter 96 non-radioactive MTT assay kit
(Promega, Madison, WI) following the manufacturer’s
instructions.
Conditioned media assay
For 5 h, GP33-specific CD8+ Teff and Tmem were cul-
tured separately or together in RPMI-1640 with 10 ng/
mL IL-2 and 0.1 μg/mL GP33 peptide (gift from Marula-
siddappa Suresh, University of Wisconsin). Conditioned
media was collected by centrifuging wells and collecting
the supernatant. For 12 h, GP33-specific CD8+ Teff and
Tmem were then co-cultured with B16GP33 melanoma
cells with or without conditioned media and anti-IL-2
(BD Biosciences, San Jose, CA) for MTT assays as de-
scribed above.
Flow cytometry
Flow cytometric analysis was performed per our previ-
ously published protocol [7–10]. Once harvested, tumor
samples were processed into single-cell suspensions with
mechanical fractionation on a fine wire mesh followed
by lymphocyte isolation using Histopaque (Sigma Al-
drich, St. Louis, MO). Splenocytes before ACT and
tumor-infiltrating lymphocytes (TIL) 4 to 14 days after
ACT were stained with APC-labeled MHC class I tetra-
mers loaded with GP33 peptide (NIH Tetramer Facility
Core, Atlanta, GA), PerCP-labeled anti-CD8 mAb,
PE-labeled anti-Ly5.1 mAb, and FITC-labeled anti-CD44
mAb (BD Biosciences, San Jose, CA). Intracellular stain-
ing required stimulation of lymphocytes with media
alone or with GP33 peptide (1 μg/mL), brefeldin A, and
recombinant human IL-2 (10 ng/mL) at 37°C for 5 h. A
BD LSRFortessa flow cytometer (BD Biosciences, San
Jose, CA) was used and data were analyzed using FlowJo
software (Tree Star Inc., Ashland, OR).
Statistical analysis
Experimental data was analyzed using IBM SPSS statis-
tical software version 23 (Armonk, NY). T-test was used
to compare groups and a repeated-measures analysis of
variance (ANOVA) with pair-wise comparisons per-
formed using Fisher’s protected least significant differ-
ence tests were used to compare multiple groups.
Significance was defined as p < 0.05, and error bars rep-
resent standard errors of the mean.
Results
Co-ACT of Teff + Tmem is more effective at inhibiting in
vivo melanoma growth than ACT of either T cell subset
alone
To verify the peptide specificity of our ACT model,
C57BL/6 mice were treated with 105 GP33-specific Teff
one day after subcutaneous inoculation with B16GP33
melanoma or parental B16F10 melanoma (which does
not express GP33). As shown in Fig. 1a-b, early ACT
strongly suppressed the growth of B16GP33 melanoma
but not B16F10 melanoma, suggesting that the effect of
ACT was peptide-specific. Moreover, the kinetics of
B16GP33 tumor growth in immunocompetent mice was
comparable to those of parental B16F10 tumor. To
compare the efficacy of ACT with different T cell
subsets, Ly5.2+/C57BL/6 mice received ACT of 105
GP33-specific CD8+ Teff, Tmem, or Teff + Tmem on day 7
after subcutaneous inoculation with 106 B16GP33 cells.
As shown in Fig. 1c-d, memory ACT resulted in signifi-
cantly greater inhibition of tumor growth compared to
effector ACT as previously described.7 Combinatorial
ACT with Teff + Tmem had significantly greater inhibition
of tumor growth compared to ACT with Teff or Tmem
separately, making this combination the most effective
strategy for ACT.
Co-ACT of Teff + Tmem promotes more potent intratumoral
CD8 + T cell infiltration than ACT of either T cell subset
alone
To determine if the efficacy of combinatorial ACT was
associated with stronger intratumoral T cell infiltration,
mice were euthanized 4 and 14 days after ACT to allow
for tumor harvesting and flow cytometric analysis of TIL
populations. Representative data shown in Fig. 2a dem-
onstrate that CD8+ T cells comprised a higher percent-
age of TIL in mice treated with ACT in comparison
with untreated controls. As shown in Fig. 2b, total num-
bers of intratumoral CD8+ were transiently elevated on
day 4 in mice treated with effector ACT, but this effect
was short-lived; in contrast, intratumoral CD8+ T cells
remain elevated on day 14 in mice treated with memory
and combinatorial ACT.
Contreras et al. Journal for ImmunoTherapy of Cancer  (2018) 6:41 Page 3 of 10
The more potent intratumoral CD8+ T cell infiltration
seen with combinatorial ACT is the result of a stronger
endogenous immune response
To characterize the increase in intratumoral CD8+ T cell
infiltration seen following ACT, flow cytometric analysis
was used to quantify the presence of Ly5.1+ adoptively
transferred CD8+ T cells and Ly5.2+ endogenous CD8+ T
cells. Representative flow cytometric data are shown as
percentages in Fig. 3a; overall data are shown as total cell
numbers in Fig. 3b-c. As shown in Fig. 3b, Ly5.1+ adop-
tively transferred CD8+ T cells comprised a small and
short-lived fraction of TIL after effector ACT but were
present in substantial and stable numbers after memory
ACT; combinatorial ACT, which used half the number of
Tmem used in memory ACT, resulted in smaller numbers
of intratumoral Ly5.1+/CD8+ TIL. In contrast, as shown
in Fig. 3c, combinatorial ACT resulted in the strongest
intratumoral infiltration of endogenous CD8+ T cells.
Combinatorial ACT results in a stronger systemic CD8+ T
cell response against tumor antigen
To determine if combinatorial ACT improved sys-
temic antitumor responsiveness in addition to local
antitumor activity, splenocytes harvested 14 days after
ACT were stimulated with or without GP33 peptide
in the presence of IL-2 and brefeldin A, and stained
to assess intracellular levels of IFNγ expression. Rep-
resentative flow cytometric data are shown as per-
centages in Fig. 4a; overall data are shown as total
cell numbers in Fig. 4b. As shown in Fig. 4b, memory
ACT resulted in stronger splenocyte reactivity to
GP33 than effector ACT, as we have previously de-
scribed.7 However, combinatorial ACT produced sig-
nificantly greater IFNγ expression among splenocytes
than memory ACT, suggesting that combinatorial
ACT may induce a much stronger level of CD8+ T
cell responsiveness to tumor antigen.
Fig. 1 ACT with a combination of Teff + Tmem resulted in optimal control of melanoma growth. Mice bearing B16GP33 (a) or B16F10 (b) melanoma
were untreated (control) or treated with ACT of 105 GP33-specific CD8+ T cells one day after tumor inoculation. Serial tumor measurements confirmed
that ACT resulted in a GP33-specific inhibition of melanoma tumor growth. (c) Mice bearing B16GP33 melanoma were treated 7 days after tumor
inoculation with no treatment (control) or 105 Teff, 10
5 Tmem, or 5 × 10
4 Teff + 5 × 10
4 Tmem. Comparison of treated groups (d) demonstrates optimal
control of melanoma growth with combinatorial ACT. This experiment was repeated three times with similar results, 4–5 mice per group. (+ p < 0.05
compared with control; * p < 0.05 compared with effector ACT; Ɨ p < 0.05 compared with memory ACT)
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Combinatorial ACT may benefit from temporal differences
in melanoma cell killing between Teff and Tmem
To further explore the improved efficacy of combinator-
ial ACT, Teff and Tmem were co-cultured in vitro with
B16GP33 melanoma cells in the presence of IL-2 for
72 h. As shown in Fig. 5, serial MTT assays demon-
strated that Teff inhibited melanoma more potently than
Tmem at 6 h. However, whereas the ability of Teff to in-
hibit melanoma was lost at later timepoints, Tmem con-
tinued to inhibit melanoma for the duration of time
points tested (up to 72 h), suggesting that the enhanced
therapeutic efficacy of combinatorial ACT could be due
to the temporal combination of early melanoma inhib-
ition mediated by Teff plus delayed but durable melan-
oma inhibition mediated by Tmem.
During combinatorial ACT, tumor cell caused by by Teff
may be enhanced by IL-2 production from Tmem
To determine if the improved efficacy of combinatorial
ACT was attributable to local interactions between cell
types, Teff, Tmem, and Teff + Tmem were co-cultured with
B16GP33 cells in the presence of IL-2 for 8 h. As shown
in Fig. 6a, whereas Teff and Tmem resulted in comparable
levels of melanoma inhibition at this time point, the
combination of Teff + Tmem resulted in a stronger level
of melanoma inhibition. To determine if this enhance-
ment was attributable to paracrine effects, Teff and Tmem
were separately stimulated with GP33 peptide for 5 h,
after which cells were pelleted by centrifugation and
conditioned media were collected. As shown in Fig. 6b,
the addition of conditioned media from Tmem enhanced
Fig. 2 Combinatorial ACT results in a stronger intratumoral T cell response. Seven days after tumor inoculation, Ly5.2+ mice were treated with
105 Teff, 10
5 Tmem, or 5 × 10
4 Teff + 5 × 10
4 Tmem derived from Ly5.1+ mice. TIL were harvested from melanoma tumors resected 4 or 14 days after
ACT and stained for flow cytometric analysis. (a) Representative TIL data (gated on lymphocyte populations) demonstrate that CD8+ T cells
comprised the highest percentage of TIL after effector ACT on day 4 and after combinatorial ACT on day 14. (b) Overall comparison of total
numbers of intratumoral CD8+ T cells on days 4 and 14 demonstrated a transient increase after effector ACT and a sustained increase after
memory ACT and combinatorial ACT. This experiment was repeated twice with similar results, 4–5 mice per group. (* p < 0.05 compared with
control condition; † p < 0.05 compared with day 4)
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Fig. 3 The stronger local CD8+ T cell response seen with combinatorial ACT is largely the result of endogenous T cell recruitment. Seven days
after tumor inoculation, Ly5.2+ mice were treated with 105 Teff, 10
5 Tmem, or 5 × 10
4 Teff + 5 × 10
4 Tmem derived from Ly5.1+ mice. Melanoma
tumors were resected 4 or 14 days after ACT and TIL were harvested for flow cytometric analysis. (a) Representative data demonstrate higher
percentages of Ly5.1+/CD8+ T cells in tumors after memory and combinatorial ACT. (b) Analysis of total numbers of Ly5.1+/CD8+ T cell
populations showed that significant and durable infiltration of adoptively transferred cells was observed after memory ACT; combinatorial ACT,
which used half the number of adoptively transferred Tmem as memory ACT, resulted in smaller numbers of intratumoral Ly5.1+/CD8+ T cells. (c)
Analysis of total numbers of Ly5.2+/CD8+ T cell populations showed that memory ACT resulted in a significant recruitment of endogenously-
derived CD8+ T cells that persisted on day 14; despite using half the number of Tmem, combinatorial ACT also resulted in durable infiltration of
endogenously-derived CD8+ T cells. This experiment was repeated twice with similar results, 4–5 mice per group. (* p < 0.05 compared with
control condition; † p < 0.05 compared with day 4)
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the ability of Teff to inhibit melanoma to a comparable
level seen with Teff + Tmem. The addition of conditioned
media from Teff did not enhance the ability of Tmem to
inhibit melanoma (data not shown). When anti-IL-2
blocking antibody was added to conditioned media from
Tmem, this effect was lost, suggesting that paracrine re-
lease of IL-2 from Tmem may potentiate tumor cell death
caused by Teff. The addition of anti-IL-2 blocking anti-
body alone did not affect the ability of Teff to inhibit
melanoma.
Discussion
For the first time, we have shown that ACT using a
combination of Teff + Tmem leads to even more robust
Fig. 4 Combinatorial ACT results in the strongest level of systemic CD8+ T cell responsiveness to tumor antigen. Seven days after tumor inoculation,
Ly5.2+ mice were treated with 105 Teff, 10
5 Tmem, or 5 × 10
4 Teff + 5 × 10
4 Tmem derived from Ly5.1+ mice. Spleens were resected 14 days after ACT and
splenocytes were incubated with media alone (control) or with tumor antigen (GP33). (a) Representative data demonstrate negligible levels of IFNγ
expression by splenocytes in response to GP33 stimulation after no ACT or effector ACT, with increasing levels seen after memory ACT
and combinatorial ACT, respectively. (b) The highest levels of IFNγ expression by splenocytes in response to GP33 stimulation were seen
after combinatorial ACT. This experiment was repeated with similar results, 4 mice per group. (* p < 0.05 compared with control condition; † p < 0.05
compared with effector ACT, ‡ p < 0.05 compared with memory ACT)
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control of melanoma growth than ACT using Teff or
Tmem alone. Our findings suggest that the advantage
of combinatorial ACT may result from the induction
of stronger infiltration of endogenous CD8+ T cells
into tumor, stronger systemic CD8+ T cell responsive-
ness to tumor antigen, temporal differences in melan-
oma cell killing, and paracrine IL-2 effects. One
recent publication addressed the effects of combining
T cell subsets prior to ACT, but this involved
co-culturing naïve cells with Tmem for 6 days prior to
ACT [11]. That approach led to a loss of
less-differentiated T cell subsets and impaired in vivo
tumor regression [11]. By combining Teff + Tmem at
the time of adoptive transfer, we were able to retain
the innate advantages of each T cell subset.
We observed that combinatorial ACT generated stron-
ger intratumoral CD8+ T cell infiltration than ACT with
Teff or Tmem alone; this was not due to greater traffick-
ing of adoptively transferred cells into tumor, but a re-
sult of more potent induction of endogenous immune
responses. This stimulation of ongoing endogenous CD8
+ T cell responses may contribute to the heightened effi-
cacy of combinatorial ACT compared to memory ACT.
We previously found that combining ACT with check-
point inhibition led to a similar induction of endogenous
TILs that was also associated with greater tumor sup-
pression, stronger systemic T cell responsiveness to
tumor antigen, and a more potent long-term anti-tumor
immunity [12]. Enhanced melanoma cell death resulting
from combinatorial ACT may promote stronger local
cytokine/chemokine release, antigen presentation, and
priming of endogenous tumor-specific T cells [13], ul-
timately promoting stronger systemic anti-tumor
immunity.
Given the innate predisposition of effector cells to rap-
idly target antigen, and the ability of memory cells to
persist and expand, we hypothesized that the ability of
Teff and Tmem to engage and inhibit melanoma would
exhibit temporal differences. Indeed, in vitro assays dem-
onstrated that Teff cause immediate but transient melan-
oma inhibition, while Tmem cause gradual but persistent
inhibition. This pattern is further reflected by the fact
that, whereas ACT with Teff resulted in a decline in
intratumoral adoptively transferred Ly5.1+/CD8+ T cells
at 14 days, ACT with Tmem resulted in stable numbers
of intratumoral transferred T cells. Thus, the activity of
effector and memory cells may be complementary over
time, leading to stronger and more prolonged melanoma
suppression.
We found that the intrinsic ability of Teff to inhibit
melanoma may also be enhanced by local production of
IL-2 by Tmem. Unlike effector Teff, Tmem are uniquely
capable of elaborating IL-2 in response to antigen stimu-
lation [2, 3]. IL-2 supplementation has long been associ-
ated with improved outcomes following ACT [14].
Systemic and local delivery of IL-2 in combination with
ACT has been shown to increase CD8+ tumor infiltra-
tion and suppression of tumor growth [1, 14–17]. With
combinatorial ACT, the local, paracrine production of
IL-2 by Tmem may mitigate the need for exogenous IL-2
administration, decreasing the risk of systemic inflam-
matory side effects.
By utilizing a melanoma expressing low levels of a
viral peptide, we are able to examine the therapeutic
effects of bona fide effector and memory differenti-
ation tumor-specific CD8+ T cells in ways not per-
missible with the use of traditional tumor antigens
(e.g., GP100). Although our B16GP33 tumor model
does not appear to be more intrinsically immunogenic
than parental B16F10 melanoma) [10], further work
will be necessary to validate our observations using
effector and memory CD8+ T cells directed against
naturally occurring melanoma antigens. Our observa-
tions suggest that a combinatorial approach to ACT
using both Teff and Tmem may be a means to optimize
the efficacy of adoptive melanoma immunotherapy.
While Teff can be readily expanded from TIL cultured
in IL-2, it is difficult to prepare large quantities of
Tmem. There is a growing body of literature character-
izing the metabolic determinants of effector versus
memory CD8+ T cell differentiation, suggesting that it
may become feasible to develop this combinatorial
approach for clinical evaluation [18–25]. This is an
area of ongoing investigation in our laboratory.
Fig. 5 Tmem and Teff have different temporal patterns of melanoma
inhibition in vitro. Teff and Tmem were co-cultured with B16GP33
melanoma cells in the presence of 10 ng/mL recombinant human
IL-2 for 72 h. Control wells contained no T cells. Serial MTT assays
were performed every 6 h. Over approximately the first 8 h, Teff
produced significantly greater inhibition of B16GP33. At all later time
points, Tmem demonstrated significantly greater suppression of
tumor growth. This experiment was repeated twice with similar
results, 3 samples per group. († p < 0.05 compared with Teff)
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Conclusions
Traditional approaches to adoptive immunotherapy
have used effector CD8+ T cells for their rapid prolif-
erative capacity and ability to engage and clear tumor
cells. Experimental evidence suggests that memory
CD8+ T cells may have physiological advantages over
effector CD8+ T cells. Our observations indicate that
a combinatorial approach to adoptive immunotherapy
using effector and memory CD8+ T cells concurrently
results in superior tumor control associated with
maximal induction of endogenous T cell responses to
tumor. This strategy appears to take advantage of
complementary differences in temporal killing of
tumor cells by effector and memory CD8+ T cells, as
well as local paracrine potentiation of effector CD8+
T cell function by memory T cell-secreted IL-2. These
findings suggest that combinatorial approaches to
cell-based immunotherapy harnessing diverse states of
T cell differentiation may open the door to even
greater therapeutic benefit.
Abbreviations
ACT: Adoptive cell transfer; LCMV: Lymphocytic choriomeningitis virus;
Teff: Effector CD8+ T cell; TIL: Tumor infiltrating lymphocyte; Tmem: Memory
CD8+ T cell
Fig. 6 Paracrine release of IL-2 from Tmem may potentiate melanoma inhibition by Teff. The local interaction of Teff and Tmem was examined by
performing in vitro melanoma inhibition assays. (a) Teff and Tmem and Teff + Tmem were co-cultured with B16GP33 for 8 h. Although melanoma
inhibition was comparable between Teff and Tmem, significantly stronger inhibition of melanoma was observed with the combination of Teff +
Tmem. (b) Conditioned media (CM) was collected from Tmem stimulated with GP33 for 5 h. The addition of CM enhanced the efficacy of Teff to a
similar degree as the addition of Tmem. The effect of CM was negated by the addition of anti-IL-2 blocking antibody; the addition of anti-IL-2
blocking antibody alone did not affect the ability of Teff to inhibit melanoma. The addition of anti-IL-2 blocking antibody blunted the ability of
Teff + Tmem to inhibit melanoma, but it could not be determined if this effect was exerted on Teff or Tmem (data not shown). This experiment was
repeated twice with similar results, 3 samples per group. (p-values as shown on horizontal bars)
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